澳大利亚在首席研究人员突然被解雇后, 停止了有前途的试验, 引发了对脊髓损伤研究的担忧. Australia halts promising paralysis trial after sudden dismissal of lead researchers, sparking concern over spinal injury research.

澳大利亚的eWalk2临床试验旨在利用电刺激恢复瘫痪病人的机动性,在Neura突然终止其主要研究人员Simon Gandevia教授和Jane Butler教授的合同后,在没有警告的情况下中断了该项试验。 The eWalk2 clinical trial in Australia, aimed at restoring mobility in paralyzed patients using electrical stimulation, has been disrupted after NeuRA abruptly terminated contracts of its lead researchers, Professors Simon Gandevia and Jane Butler, without warning. 300万美元的纳税人和慈善机构资助的项目取得了有希望的成果,使病人和研究人员感到困惑,没有明确的下一步措施。 The $3 million taxpayer and charity-funded project, which showed promising results, has left patients and researchers confused, with no clear next steps. NeuRA面临财政挑战和内部管理问题,正在努力恢复审判并返还100万美元的未动用捐款。 NeuRA, facing financial challenges and internal management issues, is working to rehome the trials and return $1 million in unspent donations. 澳大利亚脊髓损伤研究的前景越来越令人担忧,担心失去专业知识和基础设施。 Concerns are growing over the future of spinal cord injury research in Australia, with fears of lost expertise and infrastructure.